China · Delayed Price · Currency is CNY Hualan Biological Vaccine Company Description
Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetically engineered biological products in China.
The company’s main products include influenza virus split vaccine, quadrivalent influenza virus split vaccine, quadrivalent influenza virus split vaccine (pediatric formulation), H1N1 influenza A virus split vaccine, ACYW135 group meningococcal polysaccharide vaccine, recombinant hepatitis B vaccine (Hansenula polymorpha), group A and C meningococcal polysaccharide vaccine, freeze-dried human rabies vaccine (Vero cells), and adsorbed tetanus vaccine.
It also offers products under development, such as freeze-dried Group A and Group C meningococcal conjugate vaccine, adsorbed cell-free tridiphtheria-tetanus combined vaccine, freeze-dried Haemophilus influenzae type b conjugate vaccine, and recombinant zoster vaccine (CHO cells), mRNA influenza vaccines, adsorbed tetanus vaccine, and novel adjuvanted influenza vaccines.
In addition, it sells self-produced products. The company was founded in 2005 and is based in Xinxiang, China.
| Country | China |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 748 |
| CEO | Wenjue An |
Contact Details
Address: Jia No. 1-1, Hualan Avenue Xinxiang, 453003 China | |
| Phone | 86 37 3355 9909 |
| Website | hualanbacterin.com |
Stock Details
| Ticker Symbol | 301207 |
| Exchange | Shenzhen Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000058J9 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Wenjue An | GM and Director |
| Ruowen Pan | Executive Vice President and Director |
| Ke Lu | Chief Financial Officer and Secretary |